Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical
company focused on creating innovative cancer immunotherapies, today
announced that Terry Rosen, Ph.D., Chief Executive Officer, will
participate in a fireside chat at the 2018 Wedbush PacGrow Healthcare
Conference on Tuesday, August 14, 2018 at 2:30 pm ET at
the Parker New York, in New York City, NY.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused
on creating innovative cancer immunotherapies. Arcus has several
programs targeting important immuno-oncology pathways, including a dual
adenosine receptor antagonist AB928, which is being evaluated in
combination with other agents in multiple tumor types in a Phase 1/1b
program, and an anti-PD-1 antibody AB122, which is being evaluated in a
Phase 1 trial and will be tested in combination with Arcus’s other
product candidates. Arcus’s other programs include an anti-TIGIT
antibody AB154, which is in a phase 1 program, and a small molecule
inhibitor of CD73 AB680, which is in IND-enabling studies. Arcus has
extensive in-house expertise in medicinal chemistry, immunology,
biochemistry, pharmacology and structural biology. For more information
about Arcus Biosciences, please visit www.arcusbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180801005722/en/